RxDoctor Payments Data

Jessica Moldenhauer, APRN

Acute Care · Louisville, KYNPI 1659810554

Payments from drug & device makers

$358in general payments, 2019–2025

Across 12 payments — averaging $29.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$113
  • AstraZeneca$72
  • Insmed, Inc.$56
  • Stryker$50
  • Viatris Specialty LLC$27
  • Inspire Medical Systems, Inc.$25
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$31387%
  • Education$4513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 50th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,126
Medicare patients
378
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter361$293,647
OfevNintedanib Esylate11$140,103
Breztri AerosphereBudesonide/Glycopyr/Formoterol133$99,904
Dupixent PenDupilumab16$59,874
Breo ElliptaFluticasone/Vilanterol106$55,301
Spiriva RespimatTiotropium Bromide58$49,335
EliquisApixaban30$18,978
SymbicortBudesonide/Formoterol Fumarate58$18,516
Fluticasone-SalmeterolFluticasone Propion/Salmeterol88$14,756
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$14,301
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$12,721
Arnuity ElliptaFluticasone Furoate35$7,276
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate37$7,009
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$5,505
Albuterol Sulfate HfaAlbuterol Sulfate200$5,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$113$202,15991 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$72$123,925204 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 319 acute care providers in Kentucky.

Other acute care in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →